Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Regen BioPharma's Enterprise Value is $1.08 Mil.
Regen BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.51 Mil. Therefore, Regen BioPharma's EV-to-EBIT ratio for today is -2.13.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Regen BioPharma's Enterprise Value is $1.08 Mil.
Regen BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.51 Mil. Therefore, Regen BioPharma's EV-to-EBITDA ratio for today is -2.13.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Regen BioPharma's Enterprise Value is $1.08 Mil.
Regen BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $0.24 Mil. Therefore, Regen BioPharma's EV-to-Revenue ratio for today is 4.56.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Regen BioPharma's Enterprise Value is $1.08 Mil.
Regen BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.48 Mil. Therefore, Regen BioPharma's EV-to-FCF ratio for today is -2.26.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Regen BioPharma (OTCPK:RGBP) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Regen BioPharma's current Enterprise Value is $1.08 Mil.
Regen BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Regen BioPharma's current Enterprise Value is $1.08 Mil.
Regen BioPharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51 Mil.
Regen BioPharma's current Enterprise Value is $1.08 Mil.
Regen BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24 Mil.
Regen BioPharma's current Enterprise Value is $1.08 Mil.
Regen BioPharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48 Mil.
Regen BioPharma's current Enterprise Value is $1.08 Mil.
Regen BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma Enterprise Value Related Terms
Regen BioPharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs ENDV, ADTX, SCPX: Enterprise Value Comparison
For the Biotechnology subindustry, Regen BioPharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Regen BioPharma's Enterprise Value for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a Enterprise Value of $1.08 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Regen BioPharma and its competitors.
Is Regen BioPharma's Enterprise Value too high?
Regen BioPharma's current Enterprise Value is $1.08 Mil.
How does Regen BioPharma's Enterprise Value compare to ENDV and ADTX?
Regen BioPharma's Enterprise Value of $1.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current Enterprise Value is $1.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Enterprise Value is $1.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Enterprise Value is $1.08 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 